Oblique Therapeutics AB (publ) is a Swedish biotech company, developing innovative new medicines for severe diseases with a large unmet medical need, with an internal focus on pain. The company uses Abiprot®, an in-house-invented, next-generation antibody platform to discover epitopes on ‘difficult-to-target’ membrane spanning proteins.